Summit Therapeutics (SMMT) Operating Expenses (2017 - 2026)

Summit Therapeutics (SMMT) has 10 years of Operating Expenses data on file, last reported at $220.5 million in Q2 2026.

• Quarterly Operating Expenses fell 61.21% year-over-year to $220.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $874.8 million (up 15.22% YoY) and the FY2025 annual result came in at $1.1 billion, up 384.26% from the prior year.
• Operating Expenses rose to $220.5 million in Q2 2026, from $195.2 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $568.4 million in Q2 2025 to a low of $15.8 million in Q2 2023.
• A 5-year average of $135.2 million and a median of $59.0 million in 2024 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2023 — Operating Expenses jumped 1875.89% — and 2024, when it tumbled 92.12%.
• Tracing SMMT's Operating Expenses over 5 years: stood at $21.4 million in 2022, then soared by 65.12% to $35.4 million in 2023, then soared by 85.41% to $65.6 million in 2024, then soared by 242.8% to $224.9 million in 2025, then declined by 1.97% to $220.5 million in 2026.
• The last three Operating Expenses figures came in at $220.5 million (Q2 2026), $195.2 million (Q1 2026), and $224.9 million (Q4 2025), per Business Quant data.